**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 53-year-old man developed fatal interstitial pneumonitis following a negative synergistic effect of nivolumab and COVID-19.

The man with metastatic non-small-cell lung cancer, with a history of smoking, had been receiving nivolumab from June 2018. He had previously undergone treatment with carboplatin and pemetrexed in March 2018 but showed disease progression. He achieved prolonged stabilitsation on nivolumab and received 31 nivolumab administrations. He received the last nivolumab dose on 25 February 2020 without any toxicity. On 7 March 2020, he was admitted with sudden onset fever and acute dyspnea. His body temperature was 38°C and oxygen saturation at rest was 78%. A chest CT was consistent with signs of a viral infection. He also showed mild leukocytosis, neutrophilia and elevated levels of C-reactive protein and lactate dehydrogenase. A PCR analysis of COVID-19 was positive.

The man received oxygen supplementation and supportive care. He also received treatment with paracetamol, sodium chloride, morphine, haloperidol and piperacillin/tazobactam. However, his condition deteriorated rapidly and he died within 12 hrs of symptom onset from interstitial pneumonitis. His rapid clinical deterioration was thought to result from a negative synergistic effect of nivolumab and COVID-19, which possible led to a cytokine-storm resulting in fatal interstitial pneumonitis.
